Posts

Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said. The so-called bivalent vaccine targets the Beta variant – first identified in South Africa – as well as the original Wuhan strain of the virus.

California’s top state court has agreed to decide whether employers can be held liable under state law when their workers contract COVID-19 on the job and spread it to their relatives.

“Our goal is as early as August given we’re going to file all the data in June, by the end of June… hopefully in the August timeframe, the vaccine is authorised,” said Chief Executive Stephane Bancel.

FDA, HHS sued by doctors over controversial drug ivermectin Published: Jun 21, 2022 By Mark Terry BioSpace Earlier this month, three physicians filed a lawsuit against the Department of Health and Human Services (HHS), HHS Secretary Xavier Becerra, the U.S. Food and Drug Administration, and FDA Commissioner Robert M. Califf in a Texas court. They […]

The values of leading pharmaceutical brands have skyrocketed during the COVID-19 pandemic; Johnson & Johnson retains the top position.

Sanofi said an upgraded version of the COVID-19 vaccine candidate the French drugmaker is developing with GSK showed potential in two trials to protect against the virus’s main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot.

Advisers to the U.S. Food and Drug Administration will consider whether to recommend Novavax Inc.’s COVID-19 vaccine for adults, which the drugmaker hopes can become the shot of choice among some American vaccine skeptics.

The U.S. Food and Drug Administration (FDA) is on a mission to recover from the review lag seen through the early years of COVID-19 and has issued special designations for two treatments that could improve the lives of millions diagnosed with recurrent glioblastoma or hemophilia.

COVID-19 cases in the Americas increased 10.4 percent last week from the previous one, but countries must also pay attention to a rise in other respiratory viruses in the region, the Pan American Health Organization (PAHO) said on Wednesday.

Use of Pfizer Inc.’s COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time.